xanthenes has been researched along with vadimezan in 87 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 40 (45.98) | 18.2507 |
| 2000's | 46 (52.87) | 29.6817 |
| 2010's | 1 (1.15) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baguley, BC; Thomsen, LL; Wilson, WR | 1 |
| Baguley, BC; Ching, LM; Joseph, WR | 2 |
| Baguley, BC; Denny, WA; Kestell, P; McKeage, MJ | 1 |
| Baguley, BC; Ching, LM; Joseph, WR; Kestell, P; McKeage, MJ; Zwi, LJ | 1 |
| Atwell, GJ; Baguley, BC; Denny, WA; Li, ZA; Rewcastle, GW | 1 |
| Baguley, BC; Gavin, JB; Wilson, WR; Zwi, LJ | 2 |
| Barber, SA; Ching, LM; Perera, PY; Vogel, SN | 1 |
| Ellis, AG; Kestell, P; Rewcastle, GW; Webster, LK | 1 |
| Baguley, BC; Ching, LM; Gummer, BH; Joseph, WR; Palmer, BD; Xu, ZF | 1 |
| Baguley, BC; Ching, LM; Philpott, M | 2 |
| Bibby, MC; Double, JA; Laws, AL; Matthew, AM | 1 |
| Baguley, BC; Ching, LM; Joseph, WR; Zhuang, L | 1 |
| Baguley, BC; Cliffe, S; Hill, RP; Rutland, M; Taylor, ML; Wilson, WR | 1 |
| Baguley, BC; Cole, G; Li, Z; Thomsen, LL | 1 |
| Baguley, BC; Ching, LM; Crosier, KE; Joseph, WR | 1 |
| Baguley, BC; Li, Z; Thomsen, LL; Veszelovszky, E | 1 |
| Henricson, BE; Li, ZY; Manthey, CL; Perera, PY; Vogel, SN | 1 |
| Pruijn, FB; Wilson, WR | 1 |
| Denny, WA; Lee, HH; Li, AE; Patterson, LH; Pullen, SM; Thompson, KM; Wilson, WR | 1 |
| Arnold, S; Chaplin, DJ; Watts, ME | 1 |
| Begent, RH; Boden, JA; Boden, R; Boxer, GM; Flynn, AA; Keep, PA; Pedley, RB | 1 |
| Baguley, BC; Burchell, B; Kestell, P; Lillywhite, KJ; Mackenzie, PI; Miners, JO; Valente, L | 1 |
| Holford, NH; Pruijn, FB; van Daalen, M; Wilson, WR | 1 |
| Baguley, BC; Kestell, P; Zhuang, L | 1 |
| Baguley, BC; Ching, LM; Crosier, KE; Joseph, WR; Philpott, M | 1 |
| Happerfield, DW; Knowles, RG; Miles, DW; Moilanen, E; Moncada, S; Thomsen, LL | 1 |
| Baguley, BC; Browne, WL; Ching, LM; Gregory, T; Palmer, BD; Tchernegovski, R | 1 |
| Baguley, BC; Lash, CJ; Li, AE; Rutland, M; Wilson, WR; Zwi, LJ | 1 |
| Cowan, DS; Li, AE; Siim, BG; Wilson, WR | 1 |
| Baguley, BC; Cao, Z; Ching, LM; Joseph, WR; Pang, JH | 1 |
| Baguley, BC; Cao, Z; Ching, LM; Joseph, WR; Marshall, ES; Mountjoy, KG | 1 |
| Baguley, BC; Dunlop, I; Kestell, P; Paxton, JW; Rewcastle, GW | 1 |
| Baguley, BC; Browne, WL; Cao, Z; Ching, LM; Joseph, WR; Mountjoy, KG; Palmer, BD | 1 |
| Baguley, BC; Ching, LM; Goldsmith, D; Joseph, WR; Körner, H; Sedgwick, JD | 1 |
| Phillips, RM | 1 |
| Begent, RH; Boden, R; Boxer, GM; Davies, L; Pedley, RB; Sharma, SK; Springer, CJ; Stribbling, SM | 1 |
| Ching, LM; Eberly, K; Young, HA; Yu, CR | 1 |
| Kestell, P; McCall, J; Paxton, JW; Tingle, MD; Zhou, S | 1 |
| Laux, WT; Palmer, BN; Rutland, MD; Siim, BG; Wilson, WR | 1 |
| Baguley, BC; Ching, LM; Kestell, P; Muller, G; Palmer, BD; Paxton, JW; Zhao, L | 1 |
| Kestell, P; Paxton, JW; Tingle, MD; Zhou, S | 5 |
| Horsman, MR; Murata, R; Overgaard, J | 1 |
| Baguley, BC; Cao, Z; Ching, LM | 1 |
| Ching, LM; Kanwar, JR; Kanwar, RK; Krissansen, GW; Pandey, S | 1 |
| Ching, LM; Kestell, P; Paxton, JW; Tingle, MD; Zhou, S | 2 |
| Baguley, BC; Ching, LM; Kestell, P; Philpott, M; Zhao, L; Zhuang, L | 1 |
| Chin, R; Kestell, P; Paxton, JW; Tingle, MD; Zhou, S | 1 |
| Baguley, BC; Jameson, MB; Kestell, P; Paxton, JW; Thompson, PI; Tingle, MD; Zhou, SF | 1 |
| Horsman, MR; Murata, R; Overgaard, J; Siemann, DW | 1 |
| Baguley, BC; Folkes, LK; Jameson, MB; Kestell, P; Stratford, MR; Zhao, L | 1 |
| Baguley, BC | 2 |
| Baguley, BC; Ching, LM; Kestell, P; Zhao, L | 2 |
| Chiang, D; Chin, R; Kestell, P; Paxton, JW; Zho, S | 1 |
| Kestell, P; Paxton, JW; Tingle, MD; Zhou, SF | 1 |
| Beauregard, DA; Brindle, KM; Hill, SA; Pedley, RB | 1 |
| Bentzen, S; Galbraith, SM; Lodge, MA; Padhani, AR; Rustin, GJ; Stirling, JJ; Taylor, NJ | 1 |
| Lepler, S; Mercer, E; Rojiani, AM; Siemann, DW | 1 |
| Baguley, BC; Cao, Z; Ching, LM; Jameson, MB; Kieda, C; Zwain, S | 1 |
| Kestell, P; Paxton, JW; Zhou, S | 3 |
| Baguley, BC; Kestell, P; Paxton, JW; Zhou, S | 3 |
| Galbraith, SM; Gumbrell, L; Hough, D; Jameson, M; Lodge, MA; Padhani, AR; Rustin, GJ; Stirling, JJ; Taylor, NJ; Thompson, P | 1 |
| Baguley, BC; Wilson, WR | 1 |
| Baguley, BC; Ching, LM; Fraser, JD; Palmer, BD; Woon, ST | 1 |
| Atwell, GJ; Denny, WA; Yang, S | 1 |
| Baguley, BC; Ching, LM | 1 |
| Horsman, MR; Murata, R | 1 |
| Horsman, MR; Siemann, DW | 1 |
| Lee, AE; McKeage, MJ; Pruijn, FB; Shalal-Zwain, S; Siim, BG; Wilson, WR | 1 |
| Baguley, BC; Ching, LM; Newth, AL; Schooltink, MA; Woon, ST; Zwain, S | 1 |
| Baguley, BC; Bellenger, K; Evans, BD; Gumbrell, L; Halbert, GW; Harvey, VJ; Jameson, MB; Kestell, P; McCrystal, MR; Porter, DJ; Small, M; Thompson, PI | 1 |
| Barbera, M; Belluti, F; Bisi, A; Caputo, A; Carrara, M; Gobbi, S; Piazzi, L; Rampa, A; Zampiron, A | 1 |
| Baguley, BC; Ching, LM; Drummond, CJ; Kieda, C; Reddy, CB; Schooltink, MA; Woon, ST | 1 |
| Albelda, SM; Ching, LM; Guo, K; Henare, K; Palmer, BD; Tijono, SM; Wang, LC | 1 |
6 review(s) available for xanthenes and vadimezan
| Article | Year |
|---|---|
Small-molecule cytokine inducers causing tumor necrosis.
Topics: 5-Hydroxytryptophan; Animals; Antineoplastic Agents; Capillary Permeability; Cytokines; Endothelium, Vascular; Flavonoids; Humans; Interferon-alpha; Mice; Microcirculation; Necrosis; Neoplasms; NF-kappa B; Nitric Oxide; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 2001 |
5,6-dimethylxanthenone-4-acetic acid (DMXAA): a new biological response modifier for cancer therapy.
Topics: Animals; Antineoplastic Agents; Drug Interactions; Humans; Immunologic Factors; Neoplasms; Xanthenes; Xanthones | 2002 |
Potential of DMXAA combination therapy for solid tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Combined Modality Therapy; Genetic Therapy; Humans; Neoplasms; Neovascularization, Pathologic; Xanthenes; Xanthones | 2002 |
Enhancement of radiation therapy by vascular targeting agents.
Topics: Animals; Antineoplastic Agents; Drug Delivery Systems; Humans; Neovascularization, Pathologic; Organophosphorus Compounds; Xanthenes; Xanthones | 2002 |
Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation.
Topics: Animals; Antineoplastic Agents; Drug Interactions; Forecasting; Humans; Patients; Uridine Diphosphate Glucuronic Acid; Xanthenes; Xanthones | 2002 |
Antivascular therapy of cancer: DMXAA.
Topics: Antineoplastic Agents; Drug Design; Drugs, Investigational; Endothelium, Vascular; Humans; Microcirculation; Neoplasms; NF-kappa B; Xanthenes; Xanthones | 2003 |
3 trial(s) available for xanthenes and vadimezan
| Article | Year |
|---|---|
Induction of endothelial cell apoptosis by the antivascular agent 5,6-Dimethylxanthenone-4-acetic acid.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosis; Blotting, Northern; Breast Neoplasms; Cells, Cultured; Chemokine CXCL10; Chemokines, CXC; Colonic Neoplasms; Endothelium, Vascular; Female; Humans; Interferons; Mice; Mice, Inbred C57BL; Ovarian Neoplasms; RNA, Messenger; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 2002 |
Effects of 5,6-dimethylxanthenone-4-acetic acid on human tumor microcirculation assessed by dynamic contrast-enhanced magnetic resonance imaging.
Topics: Adult; Aged; Antineoplastic Agents; Area Under Curve; Contrast Media; Female; Humans; Image Enhancement; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Male; Microcirculation; Middle Aged; Muscle, Skeletal; Neoplasms; Reproducibility of Results; Xanthenes; Xanthones | 2002 |
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.
Topics: Adult; Aged; Angiogenesis Inhibitors; Antineoplastic Agents; Cardiovascular System; Female; Humans; Male; Middle Aged; Neoplasms; Nervous System; Treatment Outcome; Xanthenes; Xanthones | 2003 |
78 other study(ies) available for xanthenes and vadimezan
| Article | Year |
|---|---|
Nitric oxide: its production in host-cell-infiltrated EMT6 spheroids and its role in tumour cell killing by flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Flavonoids; Mammary Neoplasms, Experimental; Nitric Oxide; Tumor Cells, Cultured; Tumor Stem Cell Assay; Xanthenes; Xanthones | 1992 |
Stimulation of macrophage tumouricidal activity by 5,6-dimethyl-xanthenone-4-acetic acid, a potent analogue of the antitumour agent flavone-8-acetic acid.
Topics: Animals; Antineoplastic Agents; BCG Vaccine; Dose-Response Relationship, Drug; Flavonoids; Macrophage Activation; Macrophages; Mice; Mice, Inbred C3H; Thioglycolates; Tumor Cells, Cultured; Xanthenes; Xanthones | 1992 |
Antitumour responses to flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid in immune deficient mice.
Topics: Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Flavonoids; Mice; Mice, Inbred Strains; Mice, Nude; Necrosis; T-Lymphocytes; Thymectomy; Xanthenes; Xanthones | 1992 |
Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice.
Topics: Animals; Antineoplastic Agents; Blood Proteins; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Flavonoids; Male; Mice; Mice, Inbred Strains; Protein Binding; Xanthenes; Xanthones | 1991 |
Haematological effects in mice of the antitumour agents xanthenone-4-acetic acid, 5,6-dimethyl-xanthenone-4-acetic acid [correction of 5,6-methyl-] and flavone acetic acid.
Topics: Animals; Antineoplastic Agents; Blood; Blood Cells; Bone Marrow; Bone Marrow Cells; Colony-Forming Units Assay; Flavonoids; Lymphocytes; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Xanthenes; Xanthones | 1991 |
Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9H-xanthene-4-acetic acids.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Indicators and Reagents; Mice; Mice, Inbred Strains; Molecular Structure; Structure-Activity Relationship; Xanthenes; Xanthones | 1991 |
Necrosis in non-tumour tissues caused by flavone acetic acid and 5,6-dimethyl xanthenone acetic acid.
Topics: Animals; Antineoplastic Agents; Endometrium; Female; Flavonoids; Lymphoid Tissue; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Necrosis; Thrombosis; Xanthenes; Xanthones | 1990 |
Activation of LPS-inducible genes by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid in primary murine macrophages. Dissection of signaling pathways leading to gene induction and tyrosine phosphorylation.
Topics: Animals; Antineoplastic Agents; Blotting, Northern; Carbohydrate Sequence; Cells, Cultured; Female; Gene Expression Regulation; Genes, Immediate-Early; Immunoblotting; Interferons; Lipopolysaccharides; Macrophages; Mice; Mice, Inbred C3H; Molecular Sequence Data; RNA; Signal Transduction; Transcription Factors; Transcriptional Activation; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 1994 |
Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver.
Topics: Animals; Antineoplastic Agents; Bile; Flavonoids; Glucuronates; Glucuronic Acid; In Vitro Techniques; Liver; Male; Perfusion; Protein Binding; Rats; Rats, Sprague-Dawley; Xanthenes; Xanthones | 1995 |
Effect of thalidomide on tumour necrosis factor production and anti-tumour activity induced by 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Interactions; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; Thalidomide; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 1995 |
Induction of tumour necrosis factor-alpha by single and repeated doses of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid.
Topics: Aging; Animals; Antineoplastic Agents; Colonic Neoplasms; Crosses, Genetic; Dose-Response Relationship, Drug; Drug Administration Schedule; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 1995 |
Preclinical in vitro and in vivo activity of 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents; Cell Line; Cell Survival; Colonic Neoplasms; Hemorrhage; Humans; Lung Neoplasms; Mice; Mice, Inbred Strains; Mice, Nude; Necrosis; Species Specificity; Tumor Cells, Cultured; Xanthenes; Xanthones | 1995 |
Interaction between endotoxin and the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the induction of tumour necrosis factor and haemorrhagic necrosis of colon 38 tumours.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Synergism; Endotoxins; Lipopolysaccharides; Mice; Necrosis; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 1994 |
The morphological effects of the anti-tumor agents flavone acetic acid and 5,6-dimethyl xanthenone acetic acid on the colon 38 mouse tumor.
Topics: Adenocarcinoma; Adenosine Triphosphate; Animals; Apoptosis; Colonic Neoplasms; Flavonoids; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Inbred DBA; Microscopy, Electron; Necrosis; Phosphocreatine; Xanthenes; Xanthones | 1994 |
Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid.
Topics: Aniline Mustard; Animals; Antineoplastic Agents; Drug Synergism; Female; Flavonoids; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Regional Blood Flow; Tirapazamine; Triazines; Xanthenes; Xanthones | 1994 |
Serotonin involvement in the antitumour and host effects of flavone-8-acetic acid and 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Cyproheptadine; Flavonoids; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Necrosis; Nitrates; Nitric Oxide; Receptors, Serotonin; Serotonin; Serotonin Antagonists; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 1993 |
Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).
Topics: Animals; Antineoplastic Agents; Humans; Mice; Mice, Inbred C3H; Mice, Inbred C57BL; RNA, Messenger; Species Specificity; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 1994 |
Flavone acetic acid and 5,6-dimethylxanthenone-4-acetic acid: relationship between plasma nitrate elevation and the induction of tumour necrosis.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Arginine; Canavanine; Colonic Neoplasms; Flavonoids; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Inbred Strains; Necrosis; Nitrates; Nitric Oxide; Nitroarginine; omega-N-Methylarginine; Xanthenes; Xanthones | 1993 |
Dissection of LPS-induced signaling pathways in murine macrophages using LPS analogs, LPS mimetics, and agents unrelated to LPS.
Topics: Animals; Antibodies, Monoclonal; Gene Expression Regulation; In Vitro Techniques; Lipid A; Lipopolysaccharide Receptors; Lipopolysaccharides; Macrophages; Mice; Mice, Inbred C3H; Paclitaxel; Phosphoproteins; Signal Transduction; Xanthenes; Xanthones | 1995 |
Hypoxia-activated prodrugs as antitumour agents: strategies for maximizing tumour cell killing.
Topics: Aniline Mustard; Animals; Antineoplastic Agents; Cell Hypoxia; Mice; Neoplasms; Nitrogen Mustard Compounds; Prodrugs; Xanthenes; Xanthones | 1995 |
Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N.
Topics: Acridines; Animals; Anthraquinones; Antineoplastic Agents; Cell Survival; Humans; Intercalating Agents; Mammary Neoplasms, Experimental; Mice; Nitracrine; Oxidation-Reduction; Prodrugs; Xanthenes; Xanthones | 1996 |
Changes in coagulation and permeability properties of human endothelial cells in vitro induced by TNF-alpha or 5,6 MeXAA.
Topics: Antineoplastic Agents; Blood Coagulation; Capillary Permeability; Cells, Cultured; Endothelium, Vascular; Flavonoids; Humans; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 1996 |
Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow-modifying agents.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Neoplasm; Carcinoembryonic Antigen; Colorectal Neoplasms; Combined Modality Therapy; Flavonoids; Humans; Mice; Neoplasm Transplantation; Neoplasms, Experimental; Radioimmunotherapy; Regional Blood Flow; Serotonin; Tissue Distribution; Transplantation, Heterologous; Xanthenes; Xanthones | 1996 |
Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug.
Topics: Antineoplastic Agents; Glucuronates; Half-Life; Humans; Microsomes, Liver; Xanthenes; Xanthones | 1997 |
Mechanisms of enhancement of the antitumour activity of melphalan by the tumour-blood-flow inhibitor 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents, Alkylating; Cell Hypoxia; Drug Synergism; Female; Mammary Neoplasms, Experimental; Melphalan; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neovascularization, Pathologic; Xanthenes; Xanthones | 1997 |
Increased plasma serotonin following treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and colchicine: relation to vascular effects.
Topics: Animals; Antineoplastic Agents; Colchicine; Colonic Neoplasms; Dose-Response Relationship, Drug; Flavonoids; Hydroxyindoleacetic Acid; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Serotonin; Time Factors; Vinblastine; Xanthenes; Xanthones | 1997 |
Production of tumour necrosis factor-alpha by cultured human peripheral blood leucocytes in response to the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (NSC 640488).
Topics: Antineoplastic Agents; Cells, Cultured; Humans; Leukocytes; RNA, Messenger; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 1997 |
Persistent induction of nitric oxide synthase in tumours from mice treated with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents; Enzyme Induction; Immunohistochemistry; Mice; Neoplasms, Experimental; Nitrates; Nitric Oxide; Nitric Oxide Synthase; Nitrites; Ornithine; Xanthenes; Xanthones | 1998 |
Interaction of thalidomide, phthalimide analogues of thalidomide and pentoxifylline with the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid: concomitant reduction of serum tumour necrosis factor-alpha and enhancement of anti-tumour activity.
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Drug Synergism; Mice; Neoplasm Transplantation; Pentoxifylline; Phthalimides; Thalidomide; Time Factors; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 1998 |
Enhancement of the anti-tumour effects of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by combination with 5-hydroxytryptamine and bioreductive drugs.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Drug Synergism; Female; Mice; Mice, Inbred C3H; Nitrogen Mustard Compounds; Nitroimidazoles; Prodrugs; Regional Blood Flow; Serotonin; Tirapazamine; Triazines; Xanthenes; Xanthones | 1998 |
Enhancement of tumor radiation response by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Radiation; Drug Administration Schedule; Drug Screening Assays, Antitumor; Female; Mice; Mice, Inbred C3H; Neoplasm, Residual; Neoplasms, Experimental; Xanthenes; Xanthones | 1998 |
Antitumour activity of the novel immune modulator 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice lacking the interferon-gamma receptor.
Topics: Animals; Colonic Neoplasms; Cyclosporine; Enzyme-Linked Immunosorbent Assay; Immunosuppressive Agents; Interferon gamma Receptor; Interferon-gamma; Lipopolysaccharides; Mice; Nitric Oxide; Receptors, Interferon; RNA, Messenger; RNA, Neoplasm; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 1998 |
Stimulation of tumors to synthesize tumor necrosis factor-alpha in situ using 5,6-dimethylxanthenone-4-acetic acid: a novel approach to cancer therapy.
Topics: Animals; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Lipopolysaccharides; Liver; Melanoma; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; RNA, Messenger; Spleen; Stimulation, Chemical; Transplantation, Heterologous; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 1999 |
Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit.
Topics: Animals; Antineoplastic Agents; Blood Proteins; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Infusions, Intravenous; Injections, Intravenous; Male; Metabolic Clearance Rate; Mice; Protein Binding; Rabbits; Rats; Rats, Sprague-Dawley; Species Specificity; Time Factors; Xanthenes; Xanthones | 1999 |
Thalidomide increases both intra-tumoural tumour necrosis factor-alpha production and anti-tumour activity in response to 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Drug Synergism; Female; Lipopolysaccharides; Liver; Male; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Neoplasm Transplantation; RNA, Messenger; Spleen; Thalidomide; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 1999 |
Induction of intratumoral tumor necrosis factor (TNF) synthesis and hemorrhagic necrosis by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF knockout mice.
Topics: Adenocarcinoma; Animals; Antineoplastic Agents; Colonic Neoplasms; Gene Expression Regulation, Neoplastic; Hemorrhage; Mice; Mice, Inbred C57BL; Mice, Knockout; Necrosis; Neoplasm Proteins; Neovascularization, Pathologic; RNA, Messenger; RNA, Neoplasm; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 1999 |
Inhibition of DT-diaphorase (NAD(P)H:quinone oxidoreductase, EC 1.6.99.2) by 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and flavone-8-acetic acid (FAA): implications for bioreductive drug development.
Topics: Antineoplastic Agents; Aziridines; Cell Survival; Cytochrome Reductases; Cytochrome-B(5) Reductase; Enzyme Inhibitors; Flavonoids; Humans; Indolequinones; Indoles; NAD(P)H Dehydrogenase (Quinone); NADPH-Ferrihemoprotein Reductase; Tirapazamine; Triazines; Tumor Cells, Cultured; Vitamin K; Xanthenes; Xanthones | 1999 |
Enhancement of antibody-directed enzyme prodrug therapy in colorectal xenografts by an antivascular agent.
Topics: Animals; Antineoplastic Agents; Carcinoembryonic Antigen; Colorectal Neoplasms; Female; gamma-Glutamyl Hydrolase; Glutamates; Humans; Immunoconjugates; Immunoglobulin Fab Fragments; Mice; Mice, Nude; Neoplasm Transplantation; Neovascularization, Pathologic; Nitrogen Mustard Compounds; Prodrugs; Transplantation, Heterologous; Xanthenes; Xanthones | 1999 |
Induction of STAT and NFkappaB activation by the antitumor agents 5,6-dimethylxanthenone-4-acetic acid and flavone acetic acid in a murine macrophage cell line.
Topics: Animals; Antineoplastic Agents; Cell Line; Cycloheximide; DNA-Binding Proteins; Flavonoids; Interferon-beta; Lipopolysaccharides; Macrophages; Mice; NF-kappa B; Protein Synthesis Inhibitors; STAT1 Transcription Factor; STAT3 Transcription Factor; Trans-Activators; Xanthenes; Xanthones | 1999 |
Determinaton of two major metabolites of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in hepatic microsomal incubations by high-performance liquid chromatography with fluorescence detection.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Hydrogen-Ion Concentration; Hydroxides; Microsomes, Liver; NADP; Oxidation-Reduction; Phosphoric Acids; Potassium Compounds; Quality Control; Sensitivity and Specificity; Uridine Diphosphate Glucuronic Acid; Xanthenes; Xanthones | 1999 |
Scintigraphic imaging of the hypoxia marker (99m)technetium-labeled 2,2'-(1,4-diaminobutane)bis(2-methyl-3-butanone) dioxime (99mTc-labeled HL-91; prognox): noninvasive detection of tumor response to the antivascular agent 5,6-dimethylxanthenone-4-acetic
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers, Tumor; Cell Hypoxia; Fibrosarcoma; Humans; Mammary Neoplasms, Experimental; Melanoma; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms, Experimental; Organotechnetium Compounds; Oximes; Radionuclide Imaging; Radiopharmaceuticals; Stilbenes; Xanthenes; Xanthones | 2000 |
Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide.
Topics: Animals; Antineoplastic Agents; Area Under Curve; Bile; Colonic Neoplasms; Female; Half-Life; Mice; Mice, Inbred C57BL; Stereoisomerism; Thalidomide; Time Factors; Tissue Distribution; Xanthenes; Xanthones | 2000 |
Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid.
Topics: Adult; Aged; Antineoplastic Agents; Blotting, Western; Chromatography, High Pressure Liquid; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; DNA, Complementary; Female; Humans; Hydroxylation; In Vitro Techniques; Isoenzymes; Liver; Male; Methylation; Microsomes, Liver; Middle Aged; Proteins; Subcellular Fractions; Xanthenes; Xanthones | 2000 |
Comparative effects of combretastatin A-4 disodium phosphate and 5,6-dimethylxanthenone-4-acetic acid on blood perfusion in a murine tumour and normal tissues.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Blood; Digestive System; Dose-Response Relationship, Drug; Female; Kidney; Liver; Lung; Mice; Mice, Inbred C3H; Muscles; Neoplasm Transplantation; Neoplasms; Perfusion; Skin; Spleen; Stilbenes; Time Factors; Tissue Distribution; Tumor Cells, Cultured; Urinary Bladder; Xanthenes; Xanthones | 2001 |
Interferon-inducible protein 10 induction and inhibition of angiogenesis in vivo by the antitumor agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Topics: Animals; Antibodies; Antineoplastic Agents; Chemokine CCL4; Chemokine CXCL10; Chemokines, CXC; Collagen; Colonic Neoplasms; Drug Combinations; Endothelium, Vascular; Female; Fibroblast Growth Factor 2; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Interferons; Interleukin-12; Laminin; Macrophage Inflammatory Proteins; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Mice, Nude; Neovascularization, Physiologic; Proteoglycans; RNA, Messenger; Spleen; Up-Regulation; Xanthenes; Xanthones | 2001 |
Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; B7-1 Antigen; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Combined Modality Therapy; Female; Flavonoids; Gene Dosage; Genetic Therapy; Genetic Vectors; Immunotherapy; Killer Cells, Natural; Lymphocyte Subsets; Lymphoma; Mice; Mice, Inbred C57BL; Neovascularization, Pathologic; T-Lymphocytes, Cytotoxic; Thymus Neoplasms; Xanthenes; Xanthones | 2001 |
Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species.
Topics: Animals; Antineoplastic Agents; Blood Cells; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Humans; Male; Neoplasms; Protein Binding; Rabbits; Rats; Rats, Wistar; Xanthenes; Xanthones | 2001 |
In vitro and in vivo kinetic interactions of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid with thalidomide and diclofenac.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Agents; Blood Proteins; Chromatography, High Pressure Liquid; Diclofenac; Drug Interactions; Female; Humans; In Vitro Techniques; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Protein Binding; Teratogens; Thalidomide; Xanthenes; Xanthones | 2001 |
Determination of the covalent adducts of the novel anti-cancer agent 5,6-dimethylxanthenone-4-acetic acid in biological samples by high-performance liquid chromatography.
Topics: Antineoplastic Agents; Calibration; Chromatography, High Pressure Liquid; Reproducibility of Results; Sensitivity and Specificity; Serum Albumin; Xanthenes; Xanthones | 2001 |
Determination of unbound concentration of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in human plasma by ultrafiltration followed by high-performance liquid chromatography with fluorimetric detection.
Topics: Antineoplastic Agents; Calibration; Chromatography, High Pressure Liquid; Humans; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Ultrafiltration; Xanthenes; Xanthones | 2001 |
Effects of the serotonin receptor antagonist cyproheptadine on the activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Topics: Animals; Antineoplastic Agents; Colonic Neoplasms; Cyproheptadine; Drug Screening Assays, Antitumor; Drug Synergism; Drug Therapy, Combination; Female; Mice; Mice, Inbred C57BL; Mice, Inbred DBA; Serotonin Antagonists; Tissue Distribution; Xanthenes; Xanthones | 2001 |
A difference between the rat and mouse in the pharmacokinetic interaction of 5,6-dimethylxanthenone-4-acetic acid with thalidomide.
Topics: Animals; Antineoplastic Agents; Cyproheptadine; Diclofenac; Drug Interactions; Glucuronides; Hydroxylation; Male; Mice; Microsomes, Liver; Rats; Rats, Wistar; Thalidomide; Xanthenes; Xanthones | 2001 |
Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Drug Interactions; Glucuronides; Humans; In Vitro Techniques; Microsomes, Liver; Models, Biological; Xanthenes; Xanthones | 2001 |
Identification and reactivity of the major metabolite (beta-1-glucuronide) of the anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in humans.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Anticoagulants; Antineoplastic Agents; Chromatography, High Pressure Liquid; Diazepam; Dose-Response Relationship, Drug; GABA Modulators; Gas Chromatography-Mass Spectrometry; Glucuronidase; Glucuronides; Humans; Hydrogen-Ion Concentration; Hydrolysis; Male; Mice; Mice, Inbred C57BL; Models, Chemical; Phenylbutazone; Protein Binding; Rabbits; Rats; Rats, Wistar; Spectrometry, Mass, Electrospray Ionization; Time Factors; Warfarin; Xanthenes; Xanthones | 2001 |
The antitumour agent 5,6-dimethylxanthenone-4-acetic acid acts in vitro on human mononuclear cells as a co-stimulator with other inducers of tumour necrosis factor.
Topics: Antineoplastic Agents; Cell Culture Techniques; Cytokines; Dose-Response Relationship, Drug; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Humans; Leukocytes, Mononuclear; Lipopolysaccharide Receptors; Lipopolysaccharides; NF-kappa B; Okadaic Acid; Salicylic Acid; Tetradecanoylphorbol Acetate; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 2001 |
Improved tumor response by combining radiation and the vascular-damaging drug 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents; Combined Modality Therapy; Dose-Response Relationship, Drug; Dose-Response Relationship, Radiation; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Neoplasms, Experimental; Sarcoma, Experimental; Xanthenes; Xanthones | 2001 |
Measurement of plasma 5-hydroxyindoleacetic acid as a possible clinical surrogate marker for the action of antivascular agents.
Topics: Angiogenesis Inhibitors; Biomarkers; Calibration; Chromatography, High Pressure Liquid; Clinical Trials, Phase I as Topic; Electrochemistry; Humans; Hydroxyindoleacetic Acid; Neoplasms; Quality Control; Reference Standards; Regional Blood Flow; Reproducibility of Results; Solutions; Xanthenes; Xanthones | 2001 |
Oral activity and pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice.
Topics: Administration, Oral; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Colonic Neoplasms; Female; Half-Life; Hydroxyindoleacetic Acid; Injections, Intraperitoneal; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; Nitric Oxide; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 2002 |
Gender differences in the metabolism and pharmacokinetics of the experimental anticancer agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Topics: Animals; Antineoplastic Agents; Blood Proteins; Female; Humans; Male; Metabolic Clearance Rate; Mice; Mice, Inbred C57BL; Microsomes, Liver; Protein Binding; Rats; Rats, Inbred WKY; Sex Factors; Xanthenes; Xanthones | 2002 |
High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
Topics: Antineoplastic Agents; Chromatography, High Pressure Liquid; Humans; Microsomes, Liver; Reproducibility of Results; Sensitivity and Specificity; Spectrometry, Fluorescence; Xanthenes; Xanthones | 2002 |
Species differences in the metabolism of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid in vitro: implications for prediction of metabolic interactions in vivo.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Humans; In Vitro Techniques; Kidney; Liver; Mice; Microsomes; Microsomes, Liver; Neoplasms; Rabbits; Rats; Species Specificity; Xanthenes; Xanthones | 2002 |
Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS.
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Colonic Neoplasms; Contrast Media; Gadolinium DTPA; Humans; Magnetic Resonance Imaging; Magnetic Resonance Spectroscopy; Mice; Mice, SCID; Stilbenes; Transplantation, Heterologous; Xanthenes; Xanthones | 2002 |
Reproducibility of dynamic contrast-enhanced MRI in human muscle and tumours: comparison of quantitative and semi-quantitative analysis.
Topics: Antineoplastic Agents; Bibenzyls; Contrast Media; Humans; Image Processing, Computer-Assisted; Magnetic Resonance Imaging; Muscle, Skeletal; Neoplasms; Reproducibility of Results; Stilbenes; Xanthenes; Xanthones | 2002 |
Vascular targeting agents enhance chemotherapeutic agent activities in solid tumor therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood Vessels; Cisplatin; Cyclophosphamide; Dose-Response Relationship, Drug; Drug Synergism; Female; Humans; Mice; Mice, Inbred C3H; Mice, Nude; Necrosis; Neovascularization, Pathologic; Sarcoma, Experimental; Stilbenes; Tumor Cells, Cultured; Xanthenes; Xanthones | 2002 |
Strain differences in the liver microsomal metabolism of the experimental anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid in mice.
Topics: Animals; Antineoplastic Agents; Chromatography, High Pressure Liquid; Male; Mass Spectrometry; Mice; Mice, Inbred C57BL; Mice, Knockout; Microsomes, Liver; Species Specificity; Xanthenes; Xanthones | 2002 |
Non-specific binding of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in liver microsomes from various species.
Topics: Animals; Antineoplastic Agents; Binding Sites; Chromatography, High Pressure Liquid; Kinetics; Male; Mice; Mice, Inbred C57BL; Microsomes, Liver; Rabbits; Rats; Rats, Wistar; Xanthenes; Xanthones | 2002 |
The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice.
Topics: Animals; Antigens, CD; Antineoplastic Agents; Colonic Neoplasms; Dose-Response Relationship, Drug; Mice; Mice, Inbred C57BL; Mice, Knockout; Necrosis; Neoplasm Transplantation; Receptors, Tumor Necrosis Factor; Receptors, Tumor Necrosis Factor, Type I; Serotonin; Time Factors; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 2002 |
Uptake of the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and activation of NF-kappaB in human tumor cell lines.
Topics: Antineoplastic Agents; Humans; NF-kappa B; Protein Binding; Tumor Cells, Cultured; Xanthenes; Xanthones | 2002 |
An improved synthesis of 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Topics: Aniline Compounds; Antineoplastic Agents; Crystallization; Isomerism; Magnetic Resonance Spectroscopy; Nitrates; ortho-Aminobenzoates; Xanthenes; Xanthones | 2002 |
DMXAA: an antivascular agent with multiple host responses.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Hydroxyindoleacetic Acid; Mice; Mice, Inbred C57BL; Mice, Knockout; Models, Biological; Models, Chemical; Necrosis; Neoplasm Transplantation; Neovascularization, Pathologic; Nitric Oxide; Receptors, Tumor Necrosis Factor; Serotonin; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 2002 |
Combination of vascular targeting agents with thermal or radiation therapy.
Topics: Adjuvants, Immunologic; Animals; Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Dose-Response Relationship, Radiation; Flavonoids; Hyperthermia, Induced; Mice; Mice, Inbred C3H; Neoplasm Transplantation; Neoplasms; Neovascularization, Pathologic; Stilbenes; Temperature; Time Factors; Tumor Cells, Cultured; X-Rays; Xanthenes; Xanthones | 2002 |
Preclinical factors influencing the relative contributions of Phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
Topics: Animals; Antineoplastic Agents; Enzymes; Humans; Male; Microsomes, Liver; Rats; Rats, Inbred WKY; Xanthenes; Xanthones | 2003 |
Marked potentiation of the antitumour activity of chemotherapeutic drugs by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bibenzyls; Carboplatin; Dose-Response Relationship, Drug; Drug Synergism; Female; Mammary Neoplasms, Experimental; Mice; Mice, Inbred C3H; Paclitaxel; Stilbenes; Time Factors; Xanthenes; Xanthones | 2003 |
NF-kappa B activation in vivo in both host and tumour cells by the antivascular agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Topics: Adenocarcinoma; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Division; Colonic Neoplasms; Mice; Mice, Inbred C57BL; Neoplasm Transplantation; NF-kappa B; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured; Xanthenes; Xanthones | 2003 |
Preclinical factors affecting the interindividual variability in the clearance of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.
Topics: Antineoplastic Agents; Binding Sites; Blood Proteins; Cytochrome P-450 Enzyme System; Drugs, Investigational; Humans; Hydrolysis; Metabolic Clearance Rate; Microsomes, Liver; Xanthenes; Xanthones | 2003 |
New derivatives of xanthenone-4-acetic acid: synthesis, pharmacological profile and effect on TNF-alpha and NO production by human immune cells.
Topics: Cell Proliferation; Humans; Leukocytes, Mononuclear; Molecular Structure; Nitric Oxide; Stereoisomerism; Structure-Activity Relationship; Tumor Necrosis Factor-alpha; Xanthenes; Xanthones | 2006 |
A comparison of the ability of DMXAA and xanthenone analogues to activate NF-kappaB in murine and human cell lines.
Topics: Animals; Antineoplastic Agents; Biological Assay; Cell Line, Tumor; Colonic Neoplasms; Dose-Response Relationship, Drug; Endothelial Cells; Humans; Lymphoma, B-Cell; Mice; Necrosis; NF-kappa B; Structure-Activity Relationship; Xanthenes; Xanthones | 2005 |
Identification of human-selective analogues of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA).
Topics: Animals; Antineoplastic Agents; Cell Survival; Cells, Cultured; Collagen; Drug Combinations; Human Umbilical Vein Endothelial Cells; Humans; Interleukin-6; Interleukin-8; Laminin; Leukocytes; Mice; Mice, Nude; Neovascularization, Physiologic; Proteoglycans; Xanthenes; Xanthones | 2013 |